Literature DB >> 19458648

Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters.

T Husain1, M A Passini, M K Parente, N W Fraser, J H Wolfe.   

Abstract

The neurogenetic, lysosomal enzyme (LSE) deficiency diseases are characterized by storage lesions throughout the brain; therefore, gene transfer needs to provide widespread distribution of the normal enzyme. Adeno-associated virus (AAV) vectors can be effective in the brain despite limited transduction because LSEs are exported to neighboring cells (cross-correction) to reverse the metabolic deficit. The extent of correction is determined by a combination of the total amount of LSE produced by a vector and the spatial distribution of the vector within the brain. Neuron-specific promoters have been used in the brain because AAV predominantly transduces neurons. However, these promoters are large, using up a substantial amount of the limited cloning capacity of AAV vector genomes. A small promoter that is active in all cells, from the LSE beta-glucuronidase (GUSB), has been used for long-term expression in AAV vectors in the brain but the natural promoter is expressed at very low levels. The amount of LSE exported from a cell is proportional to the level of transcription, thus more active promoters would export more LSE for cross-correction, but direct comparisons have not been reported. In this study, we show that in long-term experiments (>6 months) the GUSB minimal promoter (hGBp) expresses the hGUSB enzyme in brain at similar levels as the neuron-specific enolase promoter or the promoter from the latency-associated transcript of herpes simplex virus. The hGBp minimal promoter thus may be useful for long-term expression in the central nervous system of large cDNAs, bicitronic transcription units, self-complimentary or other designs with size constraints in the AAV vector system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458648      PMCID: PMC5473363          DOI: 10.1038/gt.2009.52

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  35 in total

1.  Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream.

Authors:  Marco A Passini; Edward B Lee; Gregory G Heuer; John H Wolfe
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

2.  Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice.

Authors:  A F Skorupa; K J Fisher; J M Wilson; M K Parente; J H Wolfe
Journal:  Exp Neurol       Date:  1999-11       Impact factor: 5.330

3.  Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.

Authors:  Cassia N Cearley; John H Wolfe
Journal:  Mol Ther       Date:  2006-01-18       Impact factor: 11.454

4.  Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery.

Authors:  Haiyan Fu; Richard J Samulski; Thomas J McCown; Yoana J Picornell; David Fletcher; Joseph Muenzer
Journal:  Mol Ther       Date:  2002-01       Impact factor: 11.454

5.  Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins.

Authors:  Deborah J Watson; Gary P Kobinger; Marco A Passini; James M Wilson; John H Wolfe
Journal:  Mol Ther       Date:  2002-05       Impact factor: 11.454

6.  Adeno-associated virus vector-mediated transduction in the cat brain.

Authors:  Charles H Vite; Marco A Passini; Mark E Haskins; John H Wolfe
Journal:  Gene Ther       Date:  2003-10       Impact factor: 5.250

7.  High level expression and export of beta-glucuronidase from murine mucopolysaccharidosis VII cells corrected by a double-copy retrovirus vector.

Authors:  J H Wolfe; J W Kyle; M S Sands; W S Sly; D G Markowitz; M K Parente
Journal:  Gene Ther       Date:  1995-01       Impact factor: 5.250

8.  Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice.

Authors:  Marco A Passini; Deborah J Watson; Charles H Vite; Daniel J Landsburg; Alyson L Feigenbaum; John H Wolfe
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain.

Authors:  Cassia N Cearley; Luk H Vandenberghe; Michael K Parente; Erin R Carnish; James M Wilson; John H Wolfe
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

10.  Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery.

Authors:  Tonia Luca; Maria I Givogri; Laura Perani; Francesca Galbiati; Antonia Follenzi; Luigi Naldini; Ernesto R Bongarzone
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

View more
  18 in total

1.  Use of Adeno-Associated and Herpes Simplex Viral Vectors for In Vivo Neuronal Expression in Mice.

Authors:  Rachel D Penrod; Audrey M Wells; William A Carlezon; Christopher W Cowan
Journal:  Curr Protoc Neurosci       Date:  2015-10-01

Review 2.  Gene therapy for the neurological manifestations in lysosomal storage disorders.

Authors:  Seng H Cheng
Journal:  J Lipid Res       Date:  2014-03-29       Impact factor: 5.922

Review 3.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

Review 4.  Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy.

Authors:  Sara Kathleen Powell; Ricardo Rivera-Soto; Steven James Gray
Journal:  Discov Med       Date:  2015-01       Impact factor: 2.970

Review 5.  Progress in gene therapy for neurological disorders.

Authors:  Michele Simonato; Jean Bennett; Nicholas M Boulis; Maria G Castro; David J Fink; William F Goins; Steven J Gray; Pedro R Lowenstein; Luk H Vandenberghe; Thomas J Wilson; John H Wolfe; Joseph C Glorioso
Journal:  Nat Rev Neurol       Date:  2013-04-23       Impact factor: 42.937

6.  CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.

Authors:  Marco A Passini; Jie Bu; Eric M Roskelley; Amy M Richards; S Pablo Sardi; Catherine R O'Riordan; Katherine W Klinger; Lamya S Shihabuddin; Seng H Cheng
Journal:  J Clin Invest       Date:  2010-03-15       Impact factor: 14.808

7.  Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice.

Authors:  Hichem Tasfaout; Valentina M Lionello; Christine Kretz; Pascale Koebel; Nadia Messaddeq; Deborah Bitz; Jocelyn Laporte; Belinda S Cowling
Journal:  Mol Ther       Date:  2018-02-14       Impact factor: 11.454

8.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.

Authors:  Michael J Castle; Heikki T Turunen; Luk H Vandenberghe; John H Wolfe
Journal:  Methods Mol Biol       Date:  2016

9.  AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival.

Authors:  Rena C Baek; Marike L D Broekman; Stanley G Leroy; Laryssa A Tierney; Michael A Sandberg; Alessandra d'Azzo; Thomas N Seyfried; Miguel Sena-Esteves
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

10.  Global CNS correction in a large brain model of human alpha-mannosidosis by intravascular gene therapy.

Authors:  Sea Young Yoon; Jacqueline E Hunter; Sanjeev Chawla; Dana L Clarke; Caitlyn Molony; Patricia A O'Donnell; Jessica H Bagel; Manoj Kumar; Harish Poptani; Charles H Vite; John H Wolfe
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.